Clinical trials: Resistant Depression, Treatment
Treatment Resistant Depression
Tianeptine for Treatment Resistant Depression
The studies will be conducted in parallel at two sites: the the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai (MSSM), and Stanford Depression Research Clinic at Stanford University School of…
- Trial name
- NCT04249596
- Testing
- Tianeptine Sodium
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jonathan A. Javitch, MD, PhD
Depression, Major Depressive Disorder
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study
The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone ad-on can induce a response to antidepressants in patients with treatment resistant depression.
- Trial name
- NCT01239888
- Testing
- Oxytocin, Oxytocin and Tibolone
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- The Alfred
Major Depressive Disorder
A Study of Ketamine in Patients With Treatment-resistant Depression
The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
- Trial name
- NCT01627782
- Testing
- Ketamine
- Where
- 13 sites in United States
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
VA Aripiprazole vs Esketamine for Treatment Resistant Depression
This is an open-label, parallel-group, randomized clinical trial of up to 6 months treatment of adjunctive intranasal (IN) esketamine (ESK) vs.
- Trial name
- VAST-D II (NCT05554627)
- Testing
- Esketamine, Aripiprazole
- Where
- 26 sites in United States
- Sponsor
- VA Office of Research and Development
Depression
A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression
The purpose of this study is to explore feasibility of combining clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app with esketamine therapy in participants with Treatment-resistant Depression.
- Trial name
- NCT05268497
- Testing
- Esketamine, Cognitive Behavioral Therapy (CBT), Antidepressant
- Where
- 5 sites in United States
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder
Acute Efficacy and 6 Months Follow up After Electroconvulsive Therapy
The overall aim of the current project is to assess the acute and long term outcome of ECT (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting…
- Trial name
- NCT05388461
- Testing
- electroconvulsive therapy
- Where
- 2 sites in Norway
- Volunteers
- 600 people
- Sponsor
- Haukeland University Hospital
Depressive Disorder, Treatment-Resistant
IMPase in Treatment-resistant Depression
This experimental medicine study will examine the effects of a brief period (seven days) of 'add on' ebselen (SPI-105) treatment in patients with resistant depression to see if ebselen produces changes in emotional responses…
- Trial name
- OxIMP (NCT05117710)
- Testing
- Ebselen
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Oxford
Depression, Depressive Disorder
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
To evaluate the equivalent efficacy of ultrabrief pulsewidth right unilateral electroconvulsive therapy versus bitemporal brief pulse electroconvulsive therapy in the treatment of depression and to evaluate the cognitive effects…
- Conditions
- Depression, Depressive Disorder, Treatment Resistant Depressive Disorder, Bipolar Disorder
- Trial name
- NCT02238730
- Testing
- Ultrabrief Right Unilateral, Brief Pulse Bitemporal
- Sponsor
- Kaiser Permanente
Major Depression
Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET
This study aims at evaluating the effect of electroconvulsive therapy in treatment-resistant depressed patients on the major serotonin degrading enzyme in the human brain using neuroimaging methods, the monoamine oxidase A.
- Trial name
- NCT02379767
- Testing
- Electroconvulsive therapy, Positron emission tomography of the brain using [11C]harmine, Structural magnetic resonance imaging
- Where
- Austria
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Depression
A Randomized Sham-Controlled Study of H-Coil Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Late-Life Depression
The purpose of the study is to explore the efficacy and safety of H-Coil rTMS in comparison to a sham H-Coil rTMS in older patients with treatment-resistant major depressive disorder.Subjects will be randomized to receive H1-Coil…
- Trial name
- NCT01760681
- Testing
- H- Coil DTMS
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Shalvata Mental Health Center
Mental Disorders
Brain MRI (Magnetic Resonance Imaging) Scans of Patients With Treatment Resistant Depression (TRD) and Healthy Controls
Treatment resistant depression (TRD) is a major health concern, with 10% of patients with major depressive disorder not responding to conventional treatments.
- Trial name
- NCT01162434
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Bristol
Depression, Depressive Disorder
Buprenorphine for Treatment Resistant Depression
The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- BUP-TRD (NCT01407575)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pittsburgh
Epilepsy, Depressions, Refractory
Low Frequency TMS for Depression in Epilepsy
The purpose of this study is to determine if low-frequency transcranial magnetic stimulation (TMS) is safe and feasible for treating depressive symptoms in patients with epilepsy.
- Trial name
- LFTMS (NCT03105700)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Treatment Resistant Depression
Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression
In this study patients with treatment resistant depression, as defined by Harold Sackeim, is subjected to daily sessions, for eight weeks, with Pulsating ElectroMagnetive Treatment (PEMF).
- Trial name
- PEMFII (NCT01353092)
- Testing
- Re5 Pulsating ElectroMagnetic Fields, Re5 Pulsating ElectroMagnetic Fields (PEMF)
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Hillerod Hospital, Denmark
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Optimization of IV Ketamine for Treatment Resistant Depression
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD.
- Trial name
- NCT00768430
- Testing
- Ketamine, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Baylor College of Medicine
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of treating participants with treatment-resistant depression (TRD) who have failed at least 2 (and no more than 6) prior antidepressant (AD) treatments in the current moderate…
- Trial name
- NCT03852160
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Sponsor
- Janssen-Cilag International NV
Major Depressive Disorder (MDD)
The Effect of Transcranial Magnetic Stimulation Treatment on Microvasculature Stracture of the Retina and the Choroid
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMS_OCT-A (NCT06708013)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus, Without Associated Vestibular Pathology
Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Permanent Non-pulsatile Disabling Tinnitus (TINNOP3-DBS)
This pilot study aims at evaluating the effectiveness of the treatment of unilateral or bilateral, non-pulsatile, disabling, tinnitus, without vestibular dysfunction, using Deep Brain Stimulation (DBS) of the parieto-insular…
- Conditions
- Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus, Without Associated Vestibular Pathology, Resistant to Therapeutic Failure, With or Without Hearing Loss
- Trial name
- TINNOP3-DBS (NCT04296097)
- Testing
- DBS
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Grenoble
Major Depressive Disorder
Deep Brain Stimulation in Treatment Refractory Depression
The main aim of this trial was to investigate whether patients suffering from treatment refractory- Major Depressive Disorder (MDD) can benefit from DBS (Deep Brain Stimulation) in the brain areas known as inferior thalamic…
- Trial name
- DBSTRD (NCT01921543)
- Testing
- ITP Stimulation, CI/BNST stimulation, No stimulation
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven